Japanese startup Craif secures $22M in Series C funding to advance AI-driven cancer detection, with plans to expand in the U.S. and enhance R&D; targets increasing its miSignal test from seven to ten cancers by year-end

Craif, a Japanese early cancer detection startup using AI and microRNA, secures $22M in Series C funding, raising its total to $57M. The funds will aid U.S. expansion and R&D. Craif’s urine-based miSignal test targets seven cancers, aims to cover ten by year-end.

Source: techcrunch.com